German-based radiopharmaceutical biotech company ITM Isotope Technologies Munich and Canadian Nuclear Laboratories are launching a new joint venture company for the industrial-scale production of actinium-225, which is used in targeted alpha therapies to fight cancer. The new company is being called Actineer.